All News SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
42.47 ^USD	-3.72%		-3.72%	+16.36%

Mar. 12	Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM
Mar. 06	JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024	Apr. 18	GL
Transcript : SpringWorks Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 09:00 AM	Mar. 12
JPMorgan Adjusts Price Target on SpringWorks Therapeutics to $75 From $74, Keeps Overweight Rating	Mar. 06	MT
HC Wainwright Raises Price Target on SpringWorks Therapeutics to $74 From $73, Maintains Buy Rating	Mar. 06	MT
SpringWorks Therapeutics Starts Rolling New Drug Application for Prospective Tumor Treatment	Mar. 04	MT
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	Mar. 04	GL
SpringWorks Therapeutics, Inc. Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN	Mar. 04	CI
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	Feb. 29	GL
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors	Feb. 29	AQ
SpringWorks Therapeutics Q4 Net Loss Widens; Full-Year Net Loss Narrows	Feb. 27	MT
SpringWorks Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
SpringWorks Therapeutics: Q4 Earnings Snapshot	Feb. 27	AQ
Earnings Flash (SWTX) SPRINGWORKS THERAPEUTICS Reports Q4 Revenue $5.4M	Feb. 27	MT
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates	Feb. 27	GL
Wedbush Raises SpringWorks Therapeutics' PT to $70 From $60, Increases Sales Estimates for Ogsiveo, Mirdametinib; Keeps Outperform Rating	Feb. 26	MT
SpringWorks Therapeutics to Present at Upcoming Investor Conferences	Feb. 22	GL
Wedbush Raises SpringWorks Therapeutics' PT to $60 From $45 on Increased Valuation for Ogsiveo in Desmoid Tumors; Keeps Outperform Rating	Feb. 07	MT
Springworks Therapeutics Insider Sold Shares Worth $1,160,362, According to a Recent SEC Filing	Feb. 06	MT
SpringWorks Therapeutics, Inc. Announces Resignation of L. Mary Smith as Chief Development Officer	Feb. 02	CI
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	Jan. 31	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News SpringWorks Therapeutics, Inc.

Equities

SWTX

US85205L1070

All News

Filters